IRIS
DI MARIO, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.555
AS - Asia 31.891
EU - Europa 17.088
SA - Sud America 4.184
AF - Africa 1.589
Continente sconosciuto - Info sul continente non disponibili 801
OC - Oceania 63
Totale 91.171
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.548
SG - Singapore 11.937
CN - Cina 8.984
VN - Vietnam 4.340
IE - Irlanda 3.644
SE - Svezia 3.304
BR - Brasile 3.235
IT - Italia 2.264
HK - Hong Kong 2.077
TR - Turchia 1.525
DE - Germania 1.422
UA - Ucraina 1.265
FI - Finlandia 1.208
ZA - Sudafrica 1.087
BD - Bangladesh 1.063
FR - Francia 978
NL - Olanda 978
CA - Canada 586
GB - Regno Unito 572
RU - Federazione Russa 563
IN - India 396
AR - Argentina 341
IQ - Iraq 197
MX - Messico 195
CI - Costa d'Avorio 178
JP - Giappone 165
BE - Belgio 154
EC - Ecuador 154
ID - Indonesia 150
CO - Colombia 125
PL - Polonia 122
PH - Filippine 118
AT - Austria 109
PK - Pakistan 109
KR - Corea 99
ES - Italia 93
TH - Thailandia 93
UZ - Uzbekistan 86
VE - Venezuela 83
MA - Marocco 71
CL - Cile 69
PY - Paraguay 67
SA - Arabia Saudita 62
LT - Lituania 61
AU - Australia 59
EU - Europa 59
EG - Egitto 57
TW - Taiwan 55
RO - Romania 53
IR - Iran 49
KE - Kenya 48
AE - Emirati Arabi Uniti 46
CZ - Repubblica Ceca 44
TN - Tunisia 44
MY - Malesia 43
PE - Perù 40
IL - Israele 37
AZ - Azerbaigian 35
CR - Costa Rica 35
JM - Giamaica 35
JO - Giordania 34
HU - Ungheria 32
BO - Bolivia 31
UY - Uruguay 31
DZ - Algeria 30
BG - Bulgaria 29
PA - Panama 27
HN - Honduras 24
PT - Portogallo 24
DO - Repubblica Dominicana 23
CH - Svizzera 20
NP - Nepal 20
AL - Albania 19
KG - Kirghizistan 19
LB - Libano 18
SK - Slovacchia (Repubblica Slovacca) 17
TT - Trinidad e Tobago 17
OM - Oman 16
KZ - Kazakistan 15
RS - Serbia 14
BY - Bielorussia 12
GR - Grecia 12
GT - Guatemala 12
HR - Croazia 12
SN - Senegal 12
SV - El Salvador 12
BH - Bahrain 11
PS - Palestinian Territory 11
ET - Etiopia 10
LV - Lettonia 10
MD - Moldavia 10
GE - Georgia 9
SY - Repubblica araba siriana 9
BB - Barbados 8
DK - Danimarca 8
EE - Estonia 8
LK - Sri Lanka 8
LY - Libia 8
NI - Nicaragua 8
AM - Armenia 7
Totale 90.273
Salva come PNG Salva come JPEG
Città #
Singapore 5.586
Chandler 4.808
Ashburn 3.828
Dublin 3.632
San Jose 2.766
Santa Clara 2.306
Hong Kong 1.968
Beijing 1.839
Dearborn 1.620
Ho Chi Minh City 1.405
Nanjing 1.317
Izmir 1.236
Jacksonville 1.223
Boardman 1.190
Council Bluffs 1.139
Dallas 1.062
Johannesburg 1.027
Hanoi 976
Princeton 835
New York 815
Lauterbourg 721
Los Angeles 588
Shanghai 526
Wilmington 468
San Mateo 447
Munich 435
Moscow 433
Helsinki 426
Ann Arbor 399
Shenyang 379
Nanchang 360
Columbus 330
Toronto 313
Hebei 297
São Paulo 287
Tianjin 251
Kunming 243
Buffalo 233
Changsha 227
Jinan 227
Hefei 220
Jiaxing 203
Da Nang 180
Parma 177
Haiphong 174
Kocaeli 174
Abidjan 171
Genoa 162
Frankfurt am Main 159
Chicago 155
Milan 151
Guangzhou 149
Brussels 136
Seattle 134
The Dalles 133
Norwalk 132
Tokyo 124
Hangzhou 121
Rome 115
Tito 114
Atlanta 110
Turku 106
Zhengzhou 104
London 102
Brooklyn 96
Fremont 93
Orem 93
Pune 93
Montreal 90
Rio de Janeiro 89
Warsaw 87
Houston 86
Phoenix 85
Baghdad 77
Des Moines 77
Taranto 77
Vienna 76
Denver 75
Nardò 73
Belo Horizonte 70
Bremen 70
Stockholm 70
Hải Dương 69
Ningbo 69
San Francisco 69
Tashkent 69
Biên Hòa 66
Nuremberg 66
Chennai 61
Boston 58
Naples 58
Porto Alegre 57
Can Tho 56
Washington 54
Woodbridge 53
Curitiba 49
Quito 49
Bologna 48
Brasília 47
Mexico City 47
Totale 54.196
Salva come PNG Salva come JPEG
Nome #
L-cysteine and zinc L-carnosine in the therapy of chronic atrophic gastritis: Clinical efficacy and tolerability 706
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 513
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 450
CS1.1 EFFICACY OF MESALAMINE AND THE ASSOCIATION OF MESALAMINE AND PROBIOTICS VERSUS RIFAXIMIN IN THE TREATMENT OF SYMPTOMATIC DIVERTICULAR DISEASE 296
The effect of full-dose famotidine therapy on mucus and pepsin concentrations -b 291
Improvement of Symptoms in Patients Affected by Chronic Atrophic Gastritis Using L-Cysteine (Acetium®) 265
Coffee intake and gastroesophageal reflux: Relationship with clinical, endoscopic and functional features 250
Studio della lattoferrina nel succo pancreatico-duodenale. Limiti nelle diagnosi di pancreatite cronica 218
Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD 214
Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine 214
[Cisapride and sucralfate in dyspepsia associated with duodenogastric reflux gastritis] 208
Recovery of gastric function in patients affected by chronic atrophic gastritis using L-cysteine (Acetium®): one year survey in comparison with a control group 199
Burning Mouth Syndrome Etiology: A Narrative Review 198
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 191
Approach to gastroenterological diseases in primary care 189
Thyroid and celiac disease in pediatric age: a literature review 189
H2-blockers in the treatment of ulcer disease in the elderly 186
How and when investigating and treating Helicobacter pylori infection in children 186
Eosinophilic esophagitis in pediatric age, state of the art and review of the literature 184
Is it possible to withdrawal PPI’s therapy in GERD patients? A prospective study on 216 patients using HYCHSA 178
Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy 178
Long-term treatment for gastric and duodenal ulcer 174
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 173
Microsatellite instability in colorectal cancer 171
Individualized treatment of duodenal ulcer disease. A pilot study 171
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety 169
Endoscopic ultrasound in pediatric population: a comprehensive review of the literature 168
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 167
Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against “SARS-CoV-2 Nephropathy 167
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. 166
Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact? 166
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 165
Barrett’s esophagus: results from an Italian cohort with tight endoscopic surveillance 165
Advanced gastric cancer: the value of surgery 164
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers 163
Comparison of three different therapeutic regimens for eradicating Helicobacter pylori 163
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 162
Helicobacter pylori infection in asymptomatic elderly subjects living at home or in a nursing home: effects on gastric function and nutritional status 162
Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases 162
[Morpho-functional characteristics of reflux gastritis in patients after cholecystectomy and without cholecystectomy] 162
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 160
Current concepts in the management of helicobacter pylori infection: The maastricht III consensus report 160
Biochemical and histopathological aspects in duodenogastric reflux gastritis patients with or without prior cholecystectomy 160
A non-invasive method for the diagnosis of upper GI diseases 160
Conservative treatment of acute appendicitis 160
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 159
Association of keratin 8 gene mutation with chronic pancreatitis 159
Gastric function assessed by Gastropanel in very old patients (over 80 years old) and appropriateness of PPIs administration 159
[Clinical usefulness of the blood gastrin curve after protein meal in duodenal ulcer] 159
A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy 158
CONNECTIONS BETWEEN GENETICS ANCùD CLINICAL DATA:ROLE OF MCP-1 , CFTR AND SPINK-1 IN THE CLINICAL SETTING OF ACUTE,ACUTE RECURRENT AND CHRONIC PANCREATITIS. 158
Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study 158
Burning mouth syndrome and Reflux Disease: relationship and clinical implications 158
Epidemiology and risk factors for diverticular disease 157
Clinical markers of slow healing and relapsing gastric ulcer 157
Acid-related disorders in the elderly 156
Does chronic hypercalcemia influence serum pepsinogens levels? 156
Epidemiology and risk factors of pancreatic cancer 156
10 Day bismuth-based quadruple therapy for HP eradication in comparison with other therapies in a population with high clarithromycin resistance in northeast Italy 155
Growth changes after gluteen free diet in pediatric celiac patients: a literature-review 155
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 155
Different effects of H. pylori water extracts on cytokines, pepsinogen C and gastrin mucosal release in patients with or without duodenal ulcer 155
[Clinical usefulness of endoscopy of the upper digestive tract in the aged] 155
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. 154
Gastro panel® for detection of atrophic gastritis: The “Parma model” 154
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 154
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 152
THE SLEEPING REMNANT 152
Cimetidine, ranitidine, and pirenzepine in the treatment of duodenal ulcer: A six-month low-dose treatment period followed by a six-month observation period 152
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 152
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 151
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. 151
Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard 151
Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.--Interdisciplinary Group on Gastric Epithelial Dysplasia 151
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 150
Risk of tumor implantation in percutaneous endoscopic gastrostomy in the upper aerodigestive tumors 150
Serum pepsinogen II for early assessment of success of H. pylori eradication 150
RANITIDINA E NIZATIDINA NELL'ULCERA PEPTICA DELL'ANZIANO: STUDIO MULTICENTRICO, IN DOPPIO CIECO, A BREVE TERMINE 150
Treatment of Helicobacter pylori infection. 149
Helicobacter pylori, transmission routes and recurrence of infection: state of the art 149
ASSESSMENT OF SYMPTOMS IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD) 149
Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study 149
800 mg of cimetidine versus 300 mg of ranitidine at bedtime in the short-term treatment of duodenal ulcer: A cost/benefit study 149
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 149
Efficacy of 5-ASA in the treatment of colonic diverticular disease 149
[Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer] 149
M1695 Serum Pepsinogens and Topography of Chronic Atrophic Gastritis in a Population Sample Referred for Endoscopy 148
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 148
Follow-up in gastric dysplasia patients 148
ACID SUPPRESSION THERAPY: WHERE DO WE FROM HERE? 147
A symptom-orientated PPI strategy in the treatment of the ENT manifestations of GERD. 147
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status 147
[Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study] 147
Cancer adenomas founbd during 15 years of screening in the Alto Vicentino area (north-east Italy) 147
Global guidelines on diverticular disease of the colon: the Fiesole Consensus report 146
TERAPIA DI MANTENIMENTO PER UN ANNO CON ANTI-H2 NELL'ULCERA PEPTICA DELL'ANZIANO: IMPORTANZA DELLA SINTOMATOLOGIA COME MARKER DI RECIDIVA 146
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 145
Is the risk of contrast-induced nephropathy a real contraindication to perform intravenous contrast enhanced Computed Tomography for non-traumatic acute abdomen in Emergency Surgery Department? 145
ASPETTI METODOLOGICI DEL SONDAGGIO GASTRICO 144
[Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis] 144
Totale 17.803
Salva come PNG Salva come JPEG
Categoria #
all - tutte 330.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 330.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.555 0 23 52 224 206 59 213 444 176 310 342 1.506
2022/202314.711 1.540 1.337 984 1.304 1.153 1.798 103 1.127 4.622 60 555 128
2023/20244.820 251 577 136 136 414 1.364 214 351 145 282 398 552
2024/202516.639 347 988 1.140 853 1.997 1.879 504 660 2.511 1.562 1.396 2.802
2025/202633.219 3.017 3.075 3.337 2.646 4.984 2.242 3.491 962 4.228 2.490 1.519 1.228
2026/20273.062 1.623 1.439 0 0 0 0 0 0 0 0 0 0
Totale 91.171